This document is a publication of a United States Patent Application (US20260083755A1) filed by NEUROCRINE UK LIMITED. The application discloses a pharmaceutical composition for oral delivery containing native testosterone, along with treatment regimens and methods for addressing hormone-related conditions, specifically hypogonadism, in male, female, and transgender subjects.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property and market exclusivity for the assignee in the development and commercialization of such pharmaceutical compositions. Companies in the pharmaceutical sector, particularly those involved in hormone replacement therapies, should be aware of this filing as it may impact their R&D strategies and competitive landscape.